ArticleAntimicrobial agents and chemotherapy2006
Nanodisk-associated amphotericin B clears Leishmania major cutaneous infection in susceptible BALB/c mice.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Reconstituted HDL as a therapeutic delivery device.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2021Review
- Anti-leishmanial activity of Brevinin 2R and its Lauric acid conjugate type against L. major: In vitro mechanism of actions and in vivo treatment potentials.PLoS neglected tropical diseases · 2019Article
- Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases.The journal of venomous animals and toxins including tropical diseases · 2019Article
- Nanodiscs in Membrane Biochemistry and Biophysics.Chemical reviews · 2017Review
- Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness.Nature · 2016Article
- High-Density Lipoproteins for Therapeutic Delivery Systems.Journal of materials chemistry. B · 2016Article
- Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.PLoS neglected tropical diseases · 2015Article
- The targeted intracellular delivery of cytochrome C protein to tumors using lipid-apolipoprotein nanoparticles.Biomaterials · 2012Article
- Accelerated healing of cutaneous leishmaniasis in non-healing BALB/c mice using water soluble amphotericin B-polymethacrylic acid.Biomaterials · 2011Article
- Synthetic neoglycoconjugates of cell-surface phosphoglycans of Leishmania as potential anti-parasite carbohydrate vaccines.Biochemistry. Biokhimiia · 2011Review
- Vaults engineered for hydrophobic drug delivery.Small (Weinheim an der Bergstrasse, Germany) · 2011Article
- Curcumin nanodisks: formulation and characterization.Nanomedicine : nanotechnology, biology, and medicine · 2011Article
- Nanobiotechnology applications of reconstituted high density lipoprotein.Journal of nanobiotechnology · 2010Article
- Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis.PLoS neglected tropical diseases · 2009Article
- Nanodisks derived from amphotericin B lipid complex.Journal of pharmaceutical sciences · 2008Article
- Amphotericin B induces interdigitation of apolipoprotein stabilized nanodisk bilayers.Biochimica et biophysica acta · 2008Article
- All-trans-retinoic acid nanodisks.International journal of pharmaceutics · 2007Article
- Peptide stabilized amphotericin B nanodisks.Peptides · 2007Article
- Optimizing efficacy of Amphotericin B through nanomodification.International journal of nanomedicine · 2007Review
- Effect of Amphotericin B Nanodisks onPharmaceutica analytica actaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Nanometer-scale, apolipoprotein-stabilized phospholipid bilayer disk complexes (nanodisks [ND]) harboring the toxic and poorly soluble antileishmanial agent amphotericin B (AMB) were examined for efficacy in treatment of Leishmania major-infected BALB/c mice (Mus musculus). L. major-infected mice were intraperitoneally (i.p.) treated with AMB-ND in 0-, 1-, and 5-mg/kg doses at 24 h, 48 h, and 4, 7, 14, and 21 days postinfection in two experiments. L. major-infected mice were i.p. treated with phosphate-buffered saline, 5 mg/kg AMB-ND, or 5 mg/kg lipid-associated amphotericin B (liposomal amphotericin B, AmBisome) at 24 h, 48 h, and 10, 20, 30, and 40 days postinfection in one experiment. Parasite numbers, footpad lesion size progression, and development of cytokine responses were assayed at days 7, 15, 30, 50, 140, and 250 or at days 14, 30, 50, 95, and 140 postinfection. Mice administered AMB-ND in 1- or 5-mg/kg doses were significantly protected from L. major, displaying decreases in lesion size and parasite burden, particularly at the 5-mg/kg dosage level. In contrast to the i.p. treated AmBisome group, BALB/c mice treated with i.p. AMB-ND completely cleared an L. major infection by 140 to 250 days postinfection, with no lesions remaining and no parasites isolated from infected animals. Restimulated mixed lymphocyte culture cytokine responses (interleukin-4 [IL-4], IL-12, IL-10, NO, and gamma interferon) were unchanged by AMB-ND administration compared to controls. The marked clearance of Leishmania parasites from a susceptible strain of mice without an appreciable change in the cytokine response suggests that AMB-ND represent a potentially useful formulation for treatment of intrahistiocytic organisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.